Next 10 |
2024-05-10 13:54:26 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Instil Bio (NASDAQ: TIL ) just reported results for the first quarter of 2024. Instil Bio reported earnings per share of -$2.39. This was below the analyst estimate for EP...
2024-05-10 12:31:55 ET More on Instil Bio Instil Bio Non-GAAP EPS of -$1.26 beats by $2.14 Seeking Alpha’s Quant Rating on Instil Bio Historical earnings data for Instil Bio Financial information for Instil Bio Read the full article on Seekin...
DALLAS, May 10, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its first quarter 2024 financial results and provided a corporate update. Recent...
2024-04-16 19:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-12 09:31:55 ET More on Instil Bio Instil Bio Non-GAAP EPS of -$1.26 beats by $2.14 Instil Bio hits four-month high on rising volumes Seeking Alpha’s Quant Rating on Instil Bio Historical earnings data for Instil Bio Financial informatio...
2024-03-22 04:09:06 ET More on Instil Bio Instil Bio hits four-month high on rising volumes Seeking Alpha’s Quant Rating on Instil Bio Historical earnings data for Instil Bio Financial information for Instil Bio Read the full article on Seeki...
DALLAS, March 21, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its fourth quarter and full year 2023 financial results and provided a corporate updat...
2024-03-17 21:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-26 07:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-20 07:07:59 ET More on Iovance Biotherapeutics Iovance: Approval For Historic Solid Tumor Targeting TIL Therapy Likely, Outlook Promising Iovance Biotherapeutics: Preparing For Volatility Around Lifileucel's Upcoming PDUFA Date Iovance Biotherapeutics: The Ea...
News, Short Squeeze, Breakout and More Instantly...
DALLAS, May 10, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its first quarter 2024 financial results and provided a corporate update. Recent...
2024-04-16 19:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...